ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 47

Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity

Peter Sahlström 1, Lisa Liljefors 1, Vijay Joshua 2, Natalia Sherina 1, Radha Thyagarajan 1, Lena Israelsson 2, Ragnhild Stålesen 2, Monika Hansson 3, Khaled Amara 2, Ulf Reimer 4, Leonid Padyukov 1, Elisabet Svenungsson 5, Karin Lundberg 1, Anca Catrina 3, Lars Klareskog 3, Vivianne Malmström 2 and Caroline Grönwall2, 1Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, 3Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 4JPT Peptide Technologies, Berlin, Germany, 5Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), autoantibodies, histone acetylation and anti-CCP antibodies, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Serum anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA) display reactivity to a variety of cit-autoantigens. Studies of human ACPA mAbs have revealed that individual clones bind multiple cit-epitopes by recognition of consensus motifs. For certain ACPA, this cross-reactivity may extend also to other post-translational modifications (PTMs). Here we investigated anti-modified protein autoantibody (AMPA) reactivity to acetylated epitopes in RA.

Methods: Serum from 402 RA patients, 317 population controls and 160 SLE patients were screened by ELISA for IgG to an acetylated histone 2B peptide (His2B6-22(Ac-K12)). IgG values were normalized towards a reference and reactivities to the native lys-peptide were subtracted. Cutoff for positivity was set based on controls (Mean+3 SD Δac-lys: 4.25). ACPA fine-specificity in the RA cohort was assessed by the ISAC antigen microarray, CCP2 by CCPlus assay and RF IgM/G/A by ELiA. In addition, AMPA reactivity to Ac-His2B and His41-18(Ac-K5,8,12,16) peptides were investigated in 295 RA-derived single-cell cloned human mAbs (23 CCP2+ and 272 non-ACPA clones). A mAb-subset was further evaluated using the JPT Histone Code Array. Fisher’s exact test, Kruskal-Wallis analysis, and Spearman correlation were used for statistical analysis.

Results: RA patients displayed significant autoreactivity to acetylated histone compared to controls and SLE (Table 1, Fig. 1). Some SLE patients instead had increased reactivity to native His2B. 17% of all RA were positive for IgG anti-Ac-His2B distributing into 23% in the CCP2+ RA subset and 3.2% in CCP2 neg RA, while 0.3% in controls and 3.8% in SLE were positive. The CCP2 neg anti-Ac-His2B pos patients were RF positive and a majority had ACPA fine-specificities. At least one of the positive SLE patients was CCP2 positive. IgG anti-Ac-His2B correlated with IgG anti-CCP2 (R=0.41, p< 0.0001) as well as a range of cit-peptide reactivities (e.g. cit-Vim, cit-Fib, CEP-1). No significant association with DAS28, CRP or shared epitope HLA-DRB1 could be shown. However, levels were increased in smokers (p=0.04; Δac-lys: 3.8±9.6 RU/ml vs 1.9±6.7 RU/ml) and correlated with the number of positive ACPA fine-specificities (R=0.44 p< 0.0001). Among ACPA mAbs, 30% had ac-his reactivity (7/23, derived from 4 different patients and either lung/BAL, synovial plasma cells, or blood memory). None of the non-ACPA mAbs showed any binding. PTM cross-reactivity of these AMPA, and acetyl-lysine consensus motifs, were confirmed by the histone code array. Of note, some ACPA displayed restricted cit-reactivity.

Conclusion: A subset of ACPA can bind to acetyl-lysine peptides and elevated serum IgG anti-acetylated histone was confirmed in RA patients. We hypothesize that acetyl-autoreactivity in RA is associated with increased levels of cross-reactive AMPA. Notably, while AMPA activity is not restricted to histone motifs, anti-Ac-His may have functional properties by PAD-independent NET-interactions. These novel findings substantially extend our understanding of autoreactivity in RA and provide insight in RA pathogenesis.


Table 1 final


Fig 1 final


Disclosure: P. Sahlström, None; L. Liljefors, None; V. Joshua, None; N. Sherina, None; R. Thyagarajan, None; L. Israelsson, None; R. Stålesen, None; M. Hansson, None; K. Amara, None; U. Reimer, JPT Peptide Technologies, 3; L. Padyukov, None; E. Svenungsson, None; K. Lundberg, None; A. Catrina, None; L. Klareskog, BMS, 2, Janssen, 2, Pfizer, 2; V. Malmström, None; C. Grönwall, None.

To cite this abstract in AMA style:

Sahlström P, Liljefors L, Joshua V, Sherina N, Thyagarajan R, Israelsson L, Stålesen R, Hansson M, Amara K, Reimer U, Padyukov L, Svenungsson E, Lundberg K, Catrina A, Klareskog L, Malmström V, Grönwall C. Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/autoreactivity-to-acetylated-histones-defines-a-subset-of-ra-patients-and-is-associated-with-acetyl-citrulline-anti-modified-protein-autoantibody-ampa-cross-reactivity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoreactivity-to-acetylated-histones-defines-a-subset-of-ra-patients-and-is-associated-with-acetyl-citrulline-anti-modified-protein-autoantibody-ampa-cross-reactivity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology